Skip to main content
SpringerLink
Log in
Book cover

The Underactive Bladder pp 83–93Cite as

Current Drug Therapy for Underactive Bladder

  • Chapter

Abstract

Muscarinic agonists are the most commonly used drugs for treating the underactive bladder (UAB). Many clinicians who treat UAB patients will use bethanechol but most physicians will also acknowledge that bethanechol is not helpful for the majority of their UAB patients. Clinical utility of current parasympathomimetic treatment of UAB is limited by low pharmacologic specificity for the urinary bladder and common side effects. This chapter will review the use of parasympathetic agents to treat UAB. This will be followed by chapters that will focus on advances in treatment of UAB including Chaps. 7, 8, 9, and 10.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178

    Article  PubMed  Google Scholar 

  • Barendrecht MM, Oelke M, Laguna MP, Michel MC (2007) Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 99:749–752

    Article  CAS  PubMed  Google Scholar 

  • Barrett DM (1981) The effect of oral bethanechol chloride on voiding in female patients with excessive residual urine: a randomized double-blind study. J Urol 126:640–642

    CAS  PubMed  Google Scholar 

  • Braverman AS, Kohn IJ et al (1998) Prejunctional M1 facilitatory and M2 inhibitory muscarinic receptors mediate rat bladder contractility. Am J Physiol 274(2 Pt 2):R517–R523

    PubMed Central  CAS  PubMed  Google Scholar 

  • Burger DH, Kappetein AP, Boutkan H, Breslau PJ (1997) Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfuzosine. J Am Coll Surg 185:234–236

    Article  CAS  PubMed  Google Scholar 

  • Chancellor MB, Diokno A (2014) CURE-UAB: shedding light on the underactive bladder syndrome. Int Urol Nephrol 46(Suppl 1):S1–S46

    Article  PubMed  Google Scholar 

  • Fleming AR (1957) The use of urecholine in the prevention of postpartum urinary retention; final report. Am J Obstet Gynecol 74:569–571

    Article  CAS  PubMed  Google Scholar 

  • Gottesman L, Milsom JW, Mazier WP (1989) The use of anxiolytic and parasympathomimetic agents in the treatment of postoperative urinary retention following anorectal surgery. A prospective, randomized, double-blind study. Dis Colon Rectum 32:867–870

    Article  CAS  PubMed  Google Scholar 

  • Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147(Suppl 2):S80–S87

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Hindley RG, Brierly RD, Thomas PJ (2004) Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. BJU Int 93:89–92

    Article  CAS  PubMed  Google Scholar 

  • Kemp B, Kitschke HJ, Goetz M, Heyl W (1997) Prophylaxis and treatment of bladder dysfunction after Wertheim–Meigs operation: the positive effect of early postoperative detrusor stimulation using the cholinergic drug betanecholchloride. Int Urogynecol J Pelvic Floor Dysfunct 8:138–141

    Article  CAS  PubMed  Google Scholar 

  • Krishnamoorthy S, Kekre NS (2009) Detrusor underactivity: to tone or not to tone the bladder? Indian J Urol 25:407–408

    Article  PubMed Central  PubMed  Google Scholar 

  • Madeiro AP, Rufino AC, Sartori MG, Baracat EC, Lima GR, Girão MJ (2006) The effects of bethanechol and cisapride on urodynamic parameters in patients undergoing radical hysterectomy for cervical cancer. A randomized, double-blind, placebo-controlled study. Int Urogynecol J Pelvic Floor Dysfunct 17:248–252

    Article  PubMed  Google Scholar 

  • Manchana T, Prasartsakulchi C (2011) Bethanechol chloride for the prevention of bladder dysfunction after radical hysterectomy in gynecologic cancer patients: a randomized controlled trial study. Int J Gynecol Cancer 21:730–736

    PubMed  Google Scholar 

  • Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab F, Nitti V, Koelbl H, van Kerrebroeck P, Wein AJ (2014) Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol 65:389–398

    Article  PubMed  Google Scholar 

  • Oxford Centre for Evidence-Based Medicine: Levels of evidence and grades of recommendation (2001) Available at: http://www.cebm.net/levels_of_evidence.asp. Accessed Nov 2006

  • Riedl CR, Daha LK, Knoll M, Pflueger H (2002) Bethanechol in the restitution of the acontractile detrusor: a prospective, randomized, double blind, placebo-controlled study. Neurourol Urodyn 21:376

    Google Scholar 

  • Savona-Ventura C, Grech ES, Saliba I (1991) Pharmacological measures to prevent post-operative urinary retention; a prospective randomized study. Eur J Obstet Gynecol Reprod Biol 41:225–229

    Article  CAS  PubMed  Google Scholar 

  • Shah PJ, Abrams PH, Choa RG et al (1983) Distigmine bromide and post-prostatectomy voiding. Br J Urol 55:229–232

    Article  CAS  PubMed  Google Scholar 

  • Smith PP (2010) Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn 29:408–412

    PubMed  Google Scholar 

  • Smith PP, Tyagi P, Kuchel GA et al (2014) Advanced therapeutic directions to treat the underactive bladder. Int Urol Nephrol 46(Suppl 1):S35

    Article  PubMed  Google Scholar 

  • Somogyi GT, de Groat WC (1992) Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. J Auton Nerv Syst 37:S89–S97

    Article  Google Scholar 

  • Somogyi GT, Tanowitz M et al (1996) M1 muscarinic receptor facilitation of ACh and noradrenaline release in the rat urinary bladder is mediated by protein kinase C. J Physiol 496:245–254

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Tomoe H (2014) Assessment of the usefulness and optimal method of administration of distigmine bromide for the treatment of voiding dysfunction due to underactive detrusor. Paper presented at the AUGS/IUGA Scientific Meeting. Washington, DC. 22–26 July 2014

    Google Scholar 

  • Tyagi P, Smith PP, Kuchel GA et al (2014) Pathophysiology and animal modeling of underactive bladder. Int Urol Nephrol 46(Suppl 1):S11

    Article  PubMed Central  PubMed  Google Scholar 

  • Yamaguchi O, Shishido K et al (1996) Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 156:1208–1213

    Article  CAS  PubMed  Google Scholar 

  • Yamanishi T, Yasuda K, Kamai T et al (2004) Combination of a cholinergic drug and an α-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol 11:88–96

    Article  CAS  PubMed  Google Scholar 

  • Yoshimura N, Chancellor MB (2011) Physiology and pharmacology of the bladder and urethra. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbells urology. 10th edn Elsevier, Philadelphia, PA, USA

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Aikens Research Center, Oakland University William Beaumont School of Medicine, Rochester, MI, USA

    Michael B. Chancellor MD

  2. Neurourology Program, Beaumont Health System, Royal Oak, MI, USA

    Michael B. Chancellor MD

Authors
  1. Michael B. Chancellor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael B. Chancellor MD .

Editor information

Editors and Affiliations

  1. Department of Urology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA

    Michael B. Chancellor

  2. Department of Urology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA

    Ananias C. Diokno

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Chancellor, M.B. (2016). Current Drug Therapy for Underactive Bladder. In: Chancellor, M., Diokno, A. (eds) The Underactive Bladder. Springer, Cham. https://doi.org/10.1007/978-3-319-23687-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23687-2_6

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23686-5

  • Online ISBN: 978-3-319-23687-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation